Y-mAbs Therapeutics (YMAB) Stock Forecast, Price & News

12 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Y-mAbs Therapeutics in the last twelve months. There are currently 2 sell ratings, 5 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" YMAB shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in YMAB, but not buy additional shares or sell existing shares.
View YMAB analyst ratings or view top-rated stocks.

12 Wall Street analysts have issued 12-month price targets for Y-mAbs Therapeutics' shares. Their YMAB share price forecasts range from $4.00 to $27.00. On average, they anticipate the company's share price to reach $13.67 in the next twelve months. This suggests a possible upside of 57.1% from the stock's current price.
View analysts price targets for YMAB or view top-rated stocks among Wall Street analysts.

Y-mAbs Therapeutics' stock was trading at $4.88 at the beginning of 2023. Since then, YMAB stock has increased by 78.3% and is now trading at $8.70.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Monday, August 14th 2023.
View our YMAB earnings forecast.

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) posted its quarterly earnings data on Monday, May, 8th. The company reported ($0.15) earnings per share for the quarter, topping the consensus estimate of ($0.31) by $0.16. The company earned $20.30 million during the quarter, compared to analysts' expectations of $15.55 million. Y-mAbs Therapeutics had a negative net margin of 98.48% and a negative trailing twelve-month return on equity of 64.77%. Y-mAbs Therapeutics's revenue for the quarter was up 93.3% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($0.64) earnings per share.

Based on aggregate information from My MarketBeat watchlists, some companies that other Y-mAbs Therapeutics investors own include Bank of Hawaii (BOH), InterDigital (IDCC), STAG Industrial (STAG), Corbus Pharmaceuticals (CRBP), CTI BioPharma (CTIC), Nabriva Therapeutics (NBRV), Occidental Petroleum (OXY), VBI Vaccines (VBIV), Vaxart (VXRT) and Amarin (AMRN).

(YMAB) raised $80 million in an IPO on Friday, September 21st 2018. The company issued 5,300,000 shares at a price of $14.00-$16.00 per share. BofA Merrill Lynch, Cowen and Canaccord Genuity acted as the underwriters for the IPO and BTIG was co-manager.

Y-mAbs Therapeutics trades on the NASDAQ under the ticker symbol "YMAB."

Y-mAbs Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional investors include BlackRock Inc. (5.41%), State Street Corp (1.75%), Geode Capital Management LLC (1.52%), AIGH Capital Management LLC (0.98%), Acadian Asset Management LLC (0.91%) and Charles Schwab Investment Management Inc. (0.54%). Insiders that own company stock include Biotech Aps Wg, Bo Kruse, David N Gill, Johan Wedell-Wedellsborg, Pedro Claus Juan Moller-San, Thomas Gad and Vignesh Rajah.
View institutional ownership trends.

Shares of YMAB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of YMAB stock can currently be purchased for approximately $8.70.

Y-mAbs Therapeutics (NASDAQ:YMAB) has a market capitalization of $380.02 million and generates $65.27 million in revenue each year. The company earns $-95,570,000.00 in net income (profit) each year or ($1.69) on an earnings per share basis.

The company employs 148 workers across the globe.

Y-mAbs Therapeutics' mailing address is 230 Park Avenue Suite 3350, NEW YORK NY, 10169. The official website for the company is www.ymabs.com. The company can be reached via phone at (646) 885-8505 or via email at info@ymabs.com.